Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
Journal article published in 2005 by
Michael von Wagner,
Miriam Huber,
Thomas Berg,
Holger Hinrichsen,
Jens Rasenack,
Tobias Heintges,
Alexandra Bergk,
Christine Bernsmeier 
,
Dieter Häussinger,
Eva Herrmann,
Stefan Zeuzem
,
Dieter Häussinger,
Eva Herrmann,
Stefan Zeuzem
